The Efficacy of Selective Estrogen Receptor Modulators Monotherapies in Postmenopausal Women with Osteopenia
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: The impact of osteopenia as a risk factor for fractures is underrecognized. Moreover, the efficacy of selective estrogen receptor modulators (SERMs) in postmeno- pausal women with osteopenia is limited. This study aimed to evaluate the efficacy of SERMs in postmenopausal women with osteopenia. Methods: Thirty-two postmeno- pausal women with osteopenia were treated with 3 types of SERMs medication: raloxi- fene (group I, N = 15), bazedoxifene (group II, N = 8), and raloxifene with cholecalciferol (group III, N= 9). Bone mineral density (BMD) was measured using dual energy X-ray ab- sorptiometry scans before treatment to after 3 years of treatment once a year. Results: Patients in group I showed significant increases in hip BMD, -1.93 to -1.73 and spine BMD, -1.85 to -1.67. In addition, patients in groups II and III showed significant increases in hip BMD, -1.93 to -1.69 and -2.22 to -1.86, respectively and spine BMD, -2.1 to -1.3 and -2.22 to -1.37, respectively. The BMD increased in the hip and spine by 9.7% and 10.3%, respectively in group I, 38.0% and 12.4%, respectively in group II, and 38.2% and 16.2%, respectively in group III. Conclusions: In this study, we found that SERMs could improve spine and hip BMD. In conclusion, preemptive treatment using SERMs is necessary for postmenopausal women with osteopenia. None of the patients experienced fractures during the follow-up period.
Abstract
Background: The impact of osteopenia as a risk factor for fractures is underrecognized. Moreover, the efficacy of selective estrogen receptor modulators (SERMs) in postmeno- pausal women with osteopenia is limited. This study aimed to evaluate the efficacy of SERMs in postmenopausal women with osteopenia. Methods: Thirty-two postmeno- pausal women with osteopenia were treated with 3 types of SERMs medication: raloxi- fene (group I, N = 15), bazedoxifene (group II, N = 8), and raloxifene with cholecalciferol (group III, N= 9). Bone mineral density (BMD) was measured using dual energy X-ray ab- sorptiometry scans before treatment to after 3 years of treatment once a year. Results: Patients in group I showed significant increases in hip BMD, -1.93 to -1.73 and spine BMD, -1.85 to -1.67. In addition, patients in groups II and III showed significant increases in hip BMD, -1.93 to -1.69 and -2.22 to -1.86, respectively and spine BMD, -2.1 to -1.3 and -2.22 to -1.37, respectively. The BMD increased in the hip and spine by 9.7% and 10.3%, respectively in group I, 38.0% and 12.4%, respectively in group II, and 38.2% and 16.2%, respectively in group III. Conclusions: In this study, we found that SERMs could improve spine and hip BMD. In conclusion, preemptive treatment using SERMs is necessary for postmenopausal women with osteopenia. None of the patients experienced fractures during the follow-up period.
참고문헌 (28)
- Lin JT, "Osteoporosis: a review", Clin Orthop Relat Res, pp.126~134 (2004)
- van Staa TP, "Epidemiology of fractures in England and Wales", Bone, 29, pp.517~522 (2001)[DOI]
- "Prevention and management of osteoporosis: Report of a WHO scientific group" (2003)[URL]
- Lo SS, "Bone health status of postmenopausal Chinese women", Hong Kong Med J, 21, pp.536~541 (2015)[DOI]
- Tian L, "Prevalence of osteoporosis and related lifestyle and metabolic factors of postmenopausal women and elderly men: A cross-sectional study in Gansu province, Northwestern of China", Medicine (Baltimore), 96, pp.e8294~ (2017)[DOI]
- 박은정, "Prevalence of Osteoporosis in the Korean Population Based on Korea National Health and Nutrition Examination Survey (KNHANES), 2008--2011", Yonsei Medical Journal, 55(4), pp.1049~1057 (2014), 연세대학교의과대학[DOI]
- 백연희, "10-Year Fracture Risk in Postmenopausal Women with Osteopenia and Osteoporosis in South Korea", Endocrinology and Metabolism, 36(6), pp.1178~1188 (2021), 대한내분비학회[DOI]
- Siris ES, "Effects of risedronate on fracture risk in postmenopausal women with osteopenia", Osteoporos Int, 19, pp.681~686 (2008)[DOI]
- Siris ES, "Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women : results from the National Osteoporosis Risk Assessment", JAMA, 286, pp.2815~2822 (2001)[DOI]
- Ettinger B, "Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators", JAMA, 282, pp.637~645 (1999)[DOI]
- Bjarnason NH, "Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis", Osteoporos Int, 12, pp.922~930 (2001)[DOI]
- Cosman F, "Selective estrogen receptor modulators : clinical spectrum", Endocr Rev, 20, pp.418~434 (1999)[DOI]
- Policy brief for osteoporosis management in super-aged society, "Korean Society for Bone Mineral Research", Korean Society for Bone Mineral Research, ~ (2020)
- Riggs BL, "A unitary model for involutional osteoporosis : estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men", J Bone Miner Res, 13, pp.763~773 (1998)[DOI]
- Sahiner T, "The effects of postmenopausal hormone replacement therapy on sympathetic skin response", Maturitas, 30, pp.85~88 (1998)[DOI]
- Taranta A, "The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro", Bone, 30, pp.368~376 (2002)[DOI]
- Barrett-Connor E, "Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women", N Engl J Med, 355, pp.125~137 (2006)[DOI]
- Cauley JA, "Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation", Breast Cancer Res Treat, 65, pp.125~134 (2001)[DOI]
- Developing Korea-specific assessment criteria for osteoporosis, "National Evidence-based Healthcare Collaborating Agency", National Evidence-based Healthcare Collaborating Agency, ~ (2011)
- 권진원, "Cost-effectiveness of Pharmaceutical Interventions to Prevent Osteoporotic Fractures in Postmenopausal Women with Osteopenia", 대한골대사학회지, 23(2), pp.63~77 (2016), 대한골대사학회[DOI]
- McCombs JS, "Compliance with drug therapies for the treatment and prevention of osteoporosis", Maturitas, 48, pp.271~287 (2004)[DOI]
- Kothawala P, "Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis", Mayo Clin Proc, 82, pp.1493~1501 (2007)[DOI]
- Durden E, "Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States", Arch Osteoporos, 12, pp.22~ (2017)[DOI]
- Faulkner DL, "Patient noncompliance with hormone replacement therapy : a nationwide estimate using a large prescription claims database", Menopause, 5, pp.226~229 (1998)
- Ringe JD, "Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women", Curr Med Res Opin, 23, pp.2677~2687 (2007)[DOI]
- Kripalani S, "Interventions to enhance medication adherence in chronic medical conditions : a systematic review", Arch Intern Med, 167, pp.540~550 (2007)[DOI]
- Reid IR, "Effects of vitamin D supplements on bone mineral density : a systematic review and meta-analysis", Lancet, 383, pp.146~155 (2014)[DOI]
- Hyun Ju Liu, "Influence of Supplementary Vitamin D on Bone Mineral Density When Used in Combination with Selective Estrogen Receptor Modulators", 대한폐경학회지, 25(2), pp.94~99 (2019), 대한폐경학회[DOI]